trending Market Intelligence /marketintelligence/en/news-insights/trending/Nd1DlvLfNEd92Bgh4lTtUw2 content esgSubNav
In This List

Neuren Pharmaceuticals director to retire

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Neuren Pharmaceuticals director to retire

Neuren Pharmaceuticals Ltd. said Larry Glass would retire from the company's board, effective Dec. 31.

The company said Glass would continue to serve as the company's chief scientific officer.

Australia's Neuren Pharmaceuticals develops therapies for brain injury, neurodevelopment and neurodegenerative disorders.